.png){kind=logo}
Tempus AI stock shows 15–32% upside potential based on analyst forecasts.
The company leads in using artificial intelligence for precision healthcare.
Upcoming earnings and global expansion efforts are key growth drivers.
Tempus AI is gaining attention in the stock market for its role in using artificial intelligence (AI) to transform healthcare. The company is focused on precision medicine, using data and machine learning to help doctors treat cancer and other diseases more effectively. As of mid-July 2025, investors are watching the company closely due to recent stock movements, analyst forecasts, and expected updates from its upcoming earnings report.
Tempus AI stock is trading at $56.88 as of July 11, 2025. On that day, the stock dropped by around 4.5%. The stock has been volatile over the past year, ranging between $31.36 and $91.45. This means the price has seen both sharp rises and drops, depending on market sentiment and company developments.
The company currently has a market capitalization of approximately $9.8 billion. Its price-to-earnings (P/E) ratio remains negative, indicating that Tempus AI is still operating at a loss. However, this is common for companies that are investing heavily in growth and development, especially in high-tech sectors such as AI in healthcare.
Multiple analysts have offered their predictions for Tempus AI stock over the next 12 months. Most forecasts suggest moderate to strong upside from current levels.
The average price target from analysts is between $65 and $69, which would be a 15% to 22% increase from the current price.
The highest price target is $75, implying a possible upside of around 32%.
The lowest target is around $52 to $55, suggesting limited downside in the worst-case scenario.
Expert recommendations are generally favorable. A majority rate the stock as a "buy," while a few suggest holding the stock. No analysts have issued a "sell" rating so far.
Also Read: How to Make Money with DeepSeek: 10 Smart Strategies
Technical analysis tools also provide some insight into Tempus AI’s future movement:
Short-term signals are conflicting. A few tools show minimal bearish pressure, so it may tread water or pull back a bit before rebounding.
It has an average price target of approximately $66.70 for the next 12 months, according to several models.
The RS recently increased to 91, which means the stock is outperforming better than 91% of the market. This is a good sign of momentum going up.
The stock was supported near $55, so it has rebounded from this price in the past. If it does, the stock may start climbing once more. If it dips under $55, it may encounter additional selling.
Tempus AI fuses genomics, machine learning, and clinical data to assist physicians in making superior treatment choices. The company has a broad footprint in other areas of healthcare, such as oncology, cardiology, and radiology.
It works in more than 30 countries, partnering with hospitals, pharmaceutical firms, and research hubs. The key benefit is its reach to data from more than 50% of all US oncology clinics. This provides Tempus’s AI with a large sample to learn from and fine-tune diagnoses.
It has partnered with global companies like AstraZeneca and formed joint ventures in markets such as Japan. These partnerships help extend its worldwide reach and strengthen its technology.
While still unprofitable, Tempus is getting better with its financials. Prices for genetic sequencing are falling, which will aid margins as time goes on. While the company’s R&D spend is still high, that’s part of its multi-pronged plan to be a leader in AI-powered healthcare.
A few things could push Tempus AI stock trajectory higher over the next year:
Investors are looking forward to Tempus AI’s Q2 earnings. Strong revenue growth, signs of shrinking losses, or new partnerships can give investors confidence.
Tempus is working on real-time diagnostics for hospitals and clinics. Broader utilization of such tools might attract subscription revenue and enhance positioning.
Additional deals with pharma companies or healthcare providers could boost revenue and industry credibility.
Ongoing advancements in AI models, speed of data, and superior medical results could allow the company to beat the forecast.
Based on current data and analyst expectations, here are the three main possible scenarios:
The stock tracks solid growth with incremental improvement in earnings and technology adoption. It might reach approximately $66–69 by mid-2026, providing 15–22% returns.
Tempus delivers better-than-expected growth on new contracts and improved margins. In this case, the stock could hit $75 or above, offering 32% upside.
Slower product adoption, weaker earnings, or regulatory challenges slow down growth. The stock could drop back into its support zone of $55 or lower, which would support the gains or result in slight losses.
Tempus AI is in an incredibly promising sector, and AI and data are transforming patient care. Its robust market position, technical expertise, and alliances provide it with an advantage. Its stock is attractive for medium- to long-term investors.
While short-term volatility seems to be growing, plenty of analysts believe there’s room to run if Tempus keeps executing its plan. Earnings, additional AI diagnostics innovation, and international expansion to keep an eye on in the months ahead.
Also Read: Is AI Set to Disrupt the Future of Software as a Service (SaaS)?
Tempus AI is a high-potential but high-risk AI healthcare stock. It has the support of powerful data assets, state-of-the-art AI tools, and growing collaboration. Its $56.88 stock price implies a 15%–32% upside over the next 12 months, by most estimates. Investors should watch out for profitability lags, competition, and regulatory uncertainties. The earnings report on August 5 could be a big turning point in the stock’s trajectory ahead.
